Form 4: International Stem Cell Corp. Director Granted Significant Stock Options

Paul V. Maier, a Director at International Stem Cell Corp., was granted stock options for a total of 562,786 shares of common stock with an exercise price of $0.13 per share.

Summary

• Paul V. Maier, a Director of International Stem Cell Corp. (ISCO.OB), was granted stock options on June 17, 2025.
• The grant includes two tranches of stock options: 30,000 shares and 532,786 shares, totaling 562,786 shares.
• Both tranches have an exercise price of $0.13 per share and an expiration date of June 17, 2035.
• The 30,000 share option vests on the earlier of June 17, 2026, or the date of the next annual meeting of the Issuer's stockholders occurring after the grant date.
• The 532,786 share option vests in equal quarterly increments through June 17, 2026, with the first increment vesting on September 17, 2025.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive step in aligning management incentives with shareholder value, indicating confidence in future growth. While not a direct operational performance metric, it reflects standard corporate governance practices for compensation.

Positives

• The grant of stock options aligns the director's financial interests with those of the shareholders, incentivizing long-term value creation.
• The options have a long expiration date (June 17, 2035), providing ample time for the company's stock price to appreciate.

Negatives

• The options have no immediate cash value and their ultimate value is contingent on the future appreciation of the company's stock price above the $0.13 exercise price.
• The vesting schedules mean the director must remain with the company for a period to fully realize the benefit of the options.

Risks

• The value of the stock options is subject to market volatility and the future performance of International Stem Cell Corp.'s common stock.
• If the company's stock price does not rise above the $0.13 exercise price, the options may expire worthless.
• The vesting conditions require continued service, posing a risk if the director's tenure ends before full vesting.

Future Outlook

The grant of stock options implies an expectation of future stock price appreciation, as the options only become valuable if the share price exceeds the $0.13 exercise price. The vesting schedules tie the director's long-term compensation to the company's sustained performance through June 2026.

Industry Context

The grant of stock options is a common form of executive and director compensation in the biotechnology and life sciences sectors, including the stem cell industry. It is used to attract, retain, and incentivize key personnel by aligning their financial success with the long-term performance of the company.

Comparison to Industry Standards

• Granting stock options to directors is a standard compensation practice across various industries, including biotechnology.
• Specific comparison of the size of this grant (562,786 shares) relative to industry benchmarks would require detailed analysis of International Stem Cell Corp.'s market capitalization, the director's specific role and tenure, and typical compensation packages for similar roles in comparable companies, which is not provided in this Form 4 filing.

Related Party Transactions

• The grant of stock options to Paul V. Maier, a Director, constitutes a related party transaction as it involves compensation provided by the company to a member of its board.

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefit from aligned interests between the director and shareholder value.
• Director (Paul V. Maier): Receives a significant equity incentive, tying personal wealth to the company's stock performance.

Next Steps

• The stock options will vest according to their respective schedules, with the first increment for the larger tranche on September 17, 2025, and full vesting by June 17, 2026.
• The director may choose to exercise the options at any time after vesting and before the expiration date of June 17, 2035, assuming the stock price is favorable.

Key Dates

Keywords

International Stem Cell Corp, ISCO.OB, Stock Options, Form 4, SEC Filing, Director Compensation, Equity Grant, Paul V. Maier, Beneficial Ownership, Stem Cell